Table 5.
Statistical significance of hepatic lipid profile and malondialdehyde concentration in diabetic-hypercholesterolemic rats treated with bezafibrate, quinazolinone and halogenated derivatives
| Parameters | C | C+B | C+Q | C+BrQ | C+IQ |
| Total lipids | |||||
| Mean ± SD | 74.76 ± 7.34a | 65.00 ± 7.37a | 71.37 ± 6.01a | 65.93 ± 11.54a | 66.12 ± 9.47a |
| Range | (65.88–84.71) | (54.90–76.47) | (62.16–77.65) | (45.49–81.57) | (48.92–78.43) |
| Change% | - | -13.06 | -4.53 | -11.81 | -11.56 |
| Triacylglycerol | |||||
| Mean ± SD | 12.10 ± 3.37a | 9.90 ± 1.08a | 11.90 ± 4.38a | 12.03 ± 5.07a | 11.80 ± 4.82a |
| Range | (8.87–17.30) | (8.38–11.30) | (7.48–16.61) | (6.09–18.78) | (6.23–17.30) |
| Change% | - | -18.18 | -1.65 | -0.58 | -2.48 |
| Total cholesterol | |||||
| Mean ± SD | 26.53 ± 4.93a | 26.58 ± 3.37a | 23.87 ± 3.58a | 25.62 ± 2.94a | 26.57 ± 2.88a |
| Range | (20.05–34.15) | (21.14–31.71) | (18.79–28.86) | (23.58–32.52) | (22.08–30.08) |
| Change% | - | 0.19 | -10.03 | -3.43 | 0.15 |
| Free cholesterol | |||||
| Mean ± SD | 7.34 ± 2.45a | 7.49 ± 1.93a | 12.15 ± 2.42b | 12.40 ± 3.17b | 12.29 ± 2.59b |
| Range | (4.04–10.41) | (5.69–11.32) | (8.29–16.03) | (8.85–18.31) | (8.98–14.80) |
| Change% | - | 2.04 | 65.53 | 68.94 | 67.44 |
| Cholesterol ester | |||||
| Mean ± SD | 19.19 ± 2.61a | 19.19 ± 1.95a | 12.93 ± 2.78b | 13.34 ± 2.77b | 14.28 ± 3.82b |
| Range | (15.31–23.74) | (16.26–21.93) | (9.25–16.69) | (10.36–18.21) | (9.57–19.02) |
| Change% | - | 0 | -32.62 | -30.48 | -25.59 |
| MDA(nmol/g) | |||||
| Mean ± SD | 235.18 ± 16.32a | 238.29 ± 18.23a | 250.98 ± 12.06a | 250.23 ± 13.03a | 244.19 ± 13.45a |
| Range | (210.72–256.47) | (218.99–269.02) | (234.51–267.97) | (237.65–276.24) | (221.17–257.91) |
| Change% | - | 1.32 | 6.72 | 6.40 | 3.83 |
All parameters are expressed in mg/g tissue unless otherwise stated.
For each parameter similar characters denote insignificance between groups.
The mean difference is significant at p < 0.05.